Restoring the Double Disconnect: Towards a Conceptual Reinstatement of Opiate Addiction as a High Risk Behaviour


avatar Albert Stuart Reece 1 , *

School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, Australia

how to cite: Reece A S. Restoring the Double Disconnect: Towards a Conceptual Reinstatement of Opiate Addiction as a High Risk Behaviour. Int J High Risk Behav Addict. 2012;1(2): 47-49.



  • 1.

    World Drug Report 2009. Vienna: UN ODC; 2009.

  • 2.

    Wodak AD. Public health and politics: the demise of the ACT heroin trial. Med J Aust. 1997;167(7):348-9. [PubMed ID: 9379971].

  • 3.

    Bernard C. Leçons sur le diabète et la glycogenèse animale. 1877.

  • 4.

    Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend. 2009;105(1-2):9-15. [PubMed ID: 19608355].

  • 5.

    Darke S, Duflou J, Torok M. The comparative toxicology and major organ pathology of fatal methadone and heroin toxicity cases. Drug Alcohol Depend. 2010;106(1):1-6. [PubMed ID: 19720472].

  • 6.

    Smyth B, Hoffman V, Fan J, Hser YI. Years of potential life lost among heroin addicts 33 years after treatment. Prev Med. 2007;44(4):369-74. [PubMed ID: 17291577].

  • 7.

    Rosen D, Smith ML, Reynolds CF, 3rd. The prevalence of mental and physical health disorders among older methadone patients. Am J Geriatr Psychiatry. 2008;16(6):488-97. [PubMed ID: 18515693].

  • 8.

    Sadeghian S, Darvish S, Davoodi G, Salarifar M, Mahmoodian M, Fallah N, et al. The association of opium with coronary artery disease. Eur J Cardiovasc Prev Rehabil. 2007;14(5):715-7.

  • 9.

    Kim TW, Alford DP, Malabanan A, Holick MF, Samet JH. Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend. 2006;85(3):258-62. [PubMed ID: 16860495].

  • 10.

    Neri S, Bruno CM, Pulvirenti D, Malaguarnera M, Italiano C, Mauceri B, et al. Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology (Berl). 2005;179(3):700-4. [PubMed ID: 15806416].

  • 11.

    Reece AS. Hair graying in substance addiction. Arch Dermatol. 2007;143(1):116-8. [PubMed ID: 17224556].

  • 12.

    Reece AS, Davidson P. Deficit of circulating stem--progenitor cells in opiate addiction: a pilot study. Subst Abuse Treat Prev Policy. 2007;2:19-28. [PubMed ID: 17615060].

  • 13.

    Mousavi MR, Damghani MA, Haghdoust AA, Khamesipour A. Opium and risk of laryngeal cancer. Laryngoscope. 2003;113(11):1939-43.

  • 14.

    De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett. 2005;579(10):2035-9. [PubMed ID: 15811314].

  • 15.

    Sadeghian S, Dowlatshahi S, Karimi A, Tazik M. Epidemiology of opium use in 4398 patients admitted for coronary artery bypass graft in Tehran Heart Center. J Cardiovasc Surg (Torino). 2011;52(1):140-1.

  • 16.

    Randall D, Degenhardt L, Vajdic CM, Burns L, Hall WD, Law M, et al. Increasing cancer mortality among opioid-dependent persons in Australia: a new public health challenge for a disadvantaged population. Aust N Z J Public Health. 2011;35(3):220-5. [PubMed ID: 21627721].

  • 17.

    Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Rev. 2002;38(3):351-76.

  • 18.

    Anderson JE. A role for nitric oxide in muscle repair: nitric oxide-mediated activation of muscle satellite cells. Mol Biol Cell. 2000;11(5):1859-74. [PubMed ID: 10793157].

  • 19.

    Hutchinson MR, Shavit Y, Grace PM, Rice KC, Maier SF, Watkins LR. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev. 2011;63(3):772-810. [PubMed ID: 21752874].